DISCOVERY AND VALIDATION OF BIOMARKERS FOR NONALCOHOLIC STEATOHEPATITIS AND LIVER FIBROSIS
Grant number: 1162511 | Funding period: 2019 - 2021
Up to 80% of obese individuals have non-alcoholic fatty liver disease. A form of this disease called non-alcoholic steatohepatitis, or NASH, increases the risk of developing advanced liver disease and diabetes. Diagnosing NASH is difficult and relies on taking a liver biopsy, which is invasive and can result in complications. This project seeks to identify biomarkers of NASH from the blood of patients, which will ultimately enable early diagnosis of disease and improved patient care.
Related publications (2)
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis
Geraldine J Ooi, Peter J Meikle, Kevin Huynh, Wendy Brown, Paul Burton, Matthew J Watt
BACKGROUNDS & AIMS: Obesity often leads to non-alcoholic fatty liver disease (NAFLD), which can progress from simple steatosis (no..